CAMKK2 and intrahepatic cholangiocarcinoma: Second, our study screened bufalin as an inhibitor of CAMKK2 but did not evaluate its pharmacokinetic and pharmacodynamic properties, as well as its synergistic or antagonistic effects with other anti-ICC drugs.